Pliant Therapeutics, Inc. (PLRX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO, CA 94080

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Data as of 2021-09-19 13:27:27 -0400
Market Cap655.508 Million Shares Outstanding35.938 Million Avg 30-day Volume207.165 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.19 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.33616 52-week High/Low43.92 / 17.46 Next Earnings Date2021-11-09 Price to Cash FLow (P/CF) -45.7782
Data provided by IEX Cloud

Are you looking for these stocks instead?

View SEC Filings from PLRX instead.

View recent insider trading info

Funds Holding PLRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PLRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

20 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CUMMINGS KEITH LAMONT CHIEF FINANCIAL OFFICER

  • Officer
217,718 2021-09-03 5

PYOTT DAVID E I

  • Director
13,286 2021-06-29 4

HOMCY CHARLES J

  • Director
13,286 2021-06-29 1

CROWELL GAYLE A

  • Director
13,286 2021-06-29 1

HUH HOYOUNG

  • Director
13,286 2021-06-29 1

BRUHN SUZANNE LOUISE

  • Director
13,286 2021-06-29 1

CURNUTTE JOHN T

  • Director
13,286 2021-06-29 1

EXTER NEIL

  • Director
13,286 2021-06-29 1

SHAH SMITAL

  • Director
13,286 2021-06-29 1

LEFEBVRE ERIC CHIEF MEDICAL OFFICER

  • Officer
137,080 2021-06-18 4

COULIE BERNARD PRESIDENT AND CEO

  • Officer
  • Director
504,157 2021-06-14 8

HULL HANS CHIEF BUSINESS OFFICER

  • Officer
170,016 2021-05-26 3

HOWES BARBARA CHIEF HUMAN RESOURCE OFFICER

  • Officer
0 2021-01-23 1

OUIMETTE MIKE GENERAL COUNSEL & CORP. SEC'Y

  • Officer
0 2021-01-23 3

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

CUMMINGS KEITH LAMONT - Officer CHIEF FINANCIAL OFFICER

2021-09-03 18:27:14 -0400 2021-09-03 M 20,000 $2.08 a 67,621 direct -0.5219 -1.8789 0.0 1 -3.6534 3

CUMMINGS KEITH LAMONT - Officer CHIEF FINANCIAL OFFICER

2021-09-03 18:27:14 -0400 2021-09-03 M 20,000 d 150,097 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
PLIANT THERAPEUTICS INC PLRX 2021-09-23 22:15:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 21:45:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 21:15:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 20:45:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 20:15:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 19:45:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 19:15:03 UTC -0.4326 0.5026 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 18:45:04 UTC -0.432 0.502 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 18:15:03 UTC -0.432 0.502 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 17:45:03 UTC -0.432 0.502 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 17:15:03 UTC -0.432 0.502 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 16:45:03 UTC -0.4492 0.5192 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 16:15:03 UTC -0.4492 0.5192 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 15:45:03 UTC -0.4492 0.5192 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 15:15:03 UTC -0.4492 0.5192 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 14:45:03 UTC -0.4503 0.5203 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 14:15:03 UTC -0.4503 0.5203 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 13:45:03 UTC -0.4503 0.5203 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 13:15:03 UTC -0.4503 0.5203 100000
PLIANT THERAPEUTICS INC PLRX 2021-09-23 12:45:03 UTC -0.4503 0.5203 100000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund PLRX -1079.0 shares, $-31420.48 2021-06-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund PLRX -200.0 shares, $-5824.0 2021-06-30 N-PORT

Elevate your investments